On December 7, 2021, MOLDX held a multi-jurisdictional advisory meeting on the topic, "Predictive Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis."
The webpage is here:
This is framed as a MolDx meeting, but many of the questions were directly on the drug therapies themselves (for example, different tolerance profiles of different TNF inhibitors), and only a few questions focused on targeted diagnostics. The "PrismRA" test was mentioned a few times. See the company EXAGEN in a recent Genomeweb article.
The questions, panel ratings of the questions, and transcript are posted online, as well as links to videos. See link above or see the cut/paste below the break.
The transcript is worth reviewing for insights into the way MolDx medical directors think and the experts they were interviewing were focused and articulate.